Zobrazeno 1 - 10
of 618
pro vyhledávání: '"Godefridus J Peters"'
Autor:
Luca Costantino, Stefania Ferrari, Matteo Santucci, Outi MH Salo-Ahen, Emanuele Carosati, Silvia Franchini, Angela Lauriola, Cecilia Pozzi, Matteo Trande, Gaia Gozzi, Puneet Saxena, Giuseppe Cannazza, Lorena Losi, Daniela Cardinale, Alberto Venturelli, Antonio Quotadamo, Pasquale Linciano, Lorenzo Tagliazucchi, Maria Gaetana Moschella, Remo Guerrini, Salvatore Pacifico, Rosaria Luciani, Filippo Genovese, Stefan Henrich, Silvia Alboni, Nuno Santarem, Anabela da Silva Cordeiro, Elisa Giovannetti, Godefridus J Peters, Paolo Pinton, Alessandro Rimessi, Gabriele Cruciani, Robert M Stroud, Rebecca C Wade, Stefano Mangani, Gaetano Marverti, Domenico D'Arca, Glauco Ponterini, Maria Paola Costi
Publikováno v:
eLife, Vol 11 (2022)
Drugs that target human thymidylate synthase (hTS), a dimeric enzyme, are widely used in anticancer therapy. However, treatment with classical substrate-site-directed TS inhibitors induces over-expression of this protein and development of drug resis
Externí odkaz:
https://doaj.org/article/6b5ed787a8314e518ea035b5e470ee7c
The Cytidine Analog Fluorocyclopentenylcytosine (RX-3117) Is Activated by Uridine-Cytidine Kinase 2.
Autor:
Dzjemma Sarkisjan, Joris R Julsing, Kees Smid, Daniël de Klerk, André B P van Kuilenburg, Rutger Meinsma, Young B Lee, Deog J Kim, Godefridus J Peters
Publikováno v:
PLoS ONE, Vol 11, Iss 9, p e0162901 (2016)
Fluorocyclopentenylcytosine (RX-3117) is an orally available cytidine analog, currently in Phase I clinical trial. RX-3117 has promising antitumor activity in various human tumor xenografts including gemcitabine resistant tumors. RX-3117 is activated
Externí odkaz:
https://doaj.org/article/ecd36541f4fd43e4b410765524e870bd
Autor:
Abolfazl Avan, Amir Avan, Tessa Y S Le Large, Andrea Mambrini, Niccola Funel, Mina Maftouh, Majid Ghayour-Mobarhan, Maurizio Cantore, Ugo Boggi, Godefridus J Peters, Paola Pacetti, Elisa Giovannetti
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e108057 (2014)
Pancreatic ductal adenocarcinoma (PDAC) patients have the highest risk of developing cachexia, which is a direct cause of reduced quality of life and shorter survival. Novel biomarkers to identify patients at risk of cachexia are needed and might hav
Externí odkaz:
https://doaj.org/article/bebe4ffa80444420a10125426b584cca
Autor:
Sanne R Martens-de Kemp, Simone U Dalm, Fiona M J Wijnolts, Arjen Brink, Richard J Honeywell, Godefridus J Peters, Boudewijn J M Braakhuis, Ruud H Brakenhoff
Publikováno v:
PLoS ONE, Vol 8, Iss 4, p e61555 (2013)
PURPOSE:The combination of systemic cisplatin with local and regional radiotherapy as primary treatment of head and neck squamous cell carcinoma (HNSCC) leads to cure in approximately half of the patients. The addition of cisplatin has significant ef
Externí odkaz:
https://doaj.org/article/8c26f8b727e7492eae3d6f819991ffa7
Autor:
Virginie Frings, Astrid A M van der Veldt, Ronald Boellaard, Gerarda J M Herder, Elisa Giovannetti, Richard Honeywell, Godefridus J Peters, Erik Thunnissen, Otto S Hoekstra, Egbert F Smit
Publikováno v:
PLoS ONE, Vol 8, Iss 5, p e63705 (2013)
OBJECTIVES: Pemetrexed is a thymidylate synthase (TS) inhibitor and is effective in non-small cell lung cancer (NSCLC). 3'-deoxy-3'-[¹⁸F]fluorothymidine (¹⁸F-FLT), a proliferation marker, could potentially identify tumor specific TS-inhibition.
Externí odkaz:
https://doaj.org/article/4b96648a251d4e84a78fac5b6c02ba04
Autor:
Elisa Giovannetti, Arjan van der Velde, Niccola Funel, Enrico Vasile, Vittorio Perrone, Leticia G Leon, Nelide De Lio, Amir Avan, Sara Caponi, Luca E Pollina, Valentina Gallá, Hiroko Sudo, Alfredo Falcone, Daniela Campani, Ugo Boggi, Godefridus J Peters
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e49145 (2012)
BackgroundOnly a subset of radically resected pancreatic ductal adenocarcinoma (PDAC) patients benefit from chemotherapy, and identification of prognostic factors is warranted. Recently miRNAs emerged as diagnostic biomarkers and innovative therapeut
Externí odkaz:
https://doaj.org/article/78d81e5485f2461cb502a7b869c679ef
Autor:
Jin-Hyeok Hwang, Johannes Voortman, Elisa Giovannetti, Seth M Steinberg, Leticia G Leon, Yong-Tae Kim, Niccola Funel, Joo Kyung Park, Min A Kim, Gyeong Hoon Kang, Sun-Whe Kim, Marco Del Chiaro, Godefridus J Peters, Giuseppe Giaccone
Publikováno v:
PLoS ONE, Vol 5, Iss 5, p e10630 (2010)
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. The high risk of recurrence following surgical resection provides the rationale for adjuvant therapy. However, only a subset of patients benefit from adjuvant therapy. Identification of
Externí odkaz:
https://doaj.org/article/281cc288c786485ab873da9b3573edd6
Autor:
Godefridus J. Peters, Marika Franczak, Isabel Toenshoff, Gerrit Jansen, Ryszard T. Smolenski, Elisa Giovannetti
Publikováno v:
Franczak, M, Toenshoff, I, Jansen, G, Smolenski, R T, Giovannetti, E & Peters, G J 2023, ' The Influence of Mitochondrial Energy and 1C Metabolism on the Efficacy of Anticancer Drugs : Exploring Potential Mechanisms of Resistance ', Current Medicinal Chemistry, vol. 30, no. 11, pp. 1209-1231 . https://doi.org/10.2174/0929867329666220401110418
Abstract: Mitochondria are the main energy factory in living cells. To rapidly proliferate and metastasize, neoplastic cells increase their energy requirements. Thus, mitochondria become one of the most important organelles for them. Indeed, much res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f40dbd51ebd58d66aad7162853300939
https://doi.org/10.2174/0929867329666220401110418
https://doi.org/10.2174/0929867329666220401110418
Publikováno v:
Cancer Drug Resistance. 6:284-290
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers in humans due to late diagnosis and poor response to treatments. The tumor microenvironment (TME) of PDAC is characterized by a distinctive, suppressive immune profile, which i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::47e23d852eb99b6660117ae7d28c9c1e
https://doi.org/10.20517/cdr.2023.06
https://doi.org/10.20517/cdr.2023.06
Autor:
Marika A. Franczak, Oliwia Krol, Gabriela Harasim, Agata Jedrzejewska, Nadia Zaffaroni, Carlotta Granchi, Filippo Minutolo, Amir Avan, Elisa Giovannetti, Ryszard T. Smolenski, Godefridus J. Peters
Publikováno v:
Franczak, M A, Krol, O, Harasim, G, Jedrzejewska, A, Zaffaroni, N, Granchi, C, Minutolo, F, Avan, A, Giovannetti, E, Smolenski, R T & Peters, G J 2023, ' Metabolic Effects of New Glucose Transporter (GLUT-1) and Lactate Dehydrogenase-A (LDH-A) Inhibitors against Chemoresistant Malignant Mesothelioma ', International Journal of Molecular Sciences, vol. 24, no. 9, 7771 . https://doi.org/10.3390/ijms24097771
International Journal of Molecular Sciences, 24(9):7771. Multidisciplinary Digital Publishing Institute (MDPI)
International Journal of Molecular Sciences; Volume 24; Issue 9; Pages: 7771
International Journal of Molecular Sciences, 24(9):7771. Multidisciplinary Digital Publishing Institute (MDPI)
International Journal of Molecular Sciences; Volume 24; Issue 9; Pages: 7771
Malignant mesothelioma (MM) is a highly aggressive and resistant tumor. The prognostic role of key effectors of glycolytic metabolism in MM prompted our studies on the cytotoxicity of new inhibitors of glucose transporter type 1 (GLUT-1) and lactate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::938b29a468d9b0fdcf64801976fb54f8
https://research.vumc.nl/en/publications/3eb20e7e-7365-44bd-aa89-d88f25de0591
https://research.vumc.nl/en/publications/3eb20e7e-7365-44bd-aa89-d88f25de0591
